E-LIB Suche - Ergebnisse für: Hughes, Timothy P

1

CD302 predicts achievement of deep molecular response in pa..:

Kok, Chung Hoow ; Irani, Yazad ; Clarson, Jade...
Blood Neoplasia. 1 (2024) 2 - p. 100014 , 2024

Link: https://doi.org/10.1016/..

2

Asciminib monotherapy in patients with chronic-phase chroni..:

Cortes, Jorge E. ; Sasaki, Koji ; Kim, Dong-Wook...
Leukemia. 38 (2024) 7 - p. 1522-1533 , 2024

Link: https://doi.org/10.1038/..

3

Adverse outcomes for chronic myeloid leukemia patients with..:

Kok, Chung H. ; Saunders, Verity A. ; Dang, Phuong...
Blood Cancer Journal. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

4

Asciminib vs bosutinib in chronic-phase chronic myeloid leu..:

Hochhaus, Andreas ; Réa, Delphine ; Boquimpani, Carla...
Leukemia. 37 (2023) 3 - p. 617-626 , 2023

Link: https://doi.org/10.1038/..

5

Molecular response in newly diagnosed chronic-phase chronic..:

Radich, Jerald P. ; Wall, Matthew ; Branford, Susan...
Haematologica. 108 (2023) 6 - p. 1567-1578 , 2023

Link: https://doi.org/10.3324/..

6

The acquisition order of leukemic drug resistance mutations..:

Leow, Benjamin C. S. ; Kok, Chung H. ; Yeung, David T....
Scientific Reports. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

7

Immune modulation in chronic myeloid leukaemia patients tre..:

Irani, Yazad D. ; Hughes, Amy ; Kok, Chung H....
British Journal of Haematology. 202 (2023) 6 - p. 1127-1136 , 2023

Link: https://doi.org/10.1111/..

8

Association of TIM-3 checkpoint receptor expression on T ce..:

Irani, Yazad D. ; Kok, Chung H. ; Clarson, Jade...
Blood Advances. 7 (2023) 11 - p. 2364-2374 , 2023

Link: https://doi.org/10.1182/..

9

Asciminib monotherapy in patients with CML-CP without BCR::..:

Mauro, Michael J. ; Hughes, Timothy P. ; Kim, Dong-Wook...
Leukemia. 37 (2023) 5 - p. 1048-1059 , 2023

Link: https://doi.org/10.1038/..

10

Impact of additional genetic abnormalities at diagnosis of ..:

Shanmuganathan, Naranie ; Wadham, Carol ; Shahrin, NurHezrin...
Haematologica. , 2023

Link: https://doi.org/10.3324/..

11

CML-395 Efficacy and Safety Results From ASCEMBL, a Phase I..:

Réa, Delphine ; Hochhaus, Andreas ; Mauro, Michael J....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S295-S296 , 2022

Link: https://doi.org/10.1016/..

12

Poster: CML-466 Asciminib Provides Durable Molecular Respon..:

Hughes, Timothy P. ; Cortes, Jorge E. ; Réa, Delphine...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S146 , 2022

Link: https://doi.org/10.1016/..

13

Asciminib for chronic myeloid leukaemia: Next questions:

Shanmuganathan, Naranie ; Hughes, Timothy P.
British Journal of Haematology. 199 (2022) 3 - p. 322-331 , 2022

Link: https://doi.org/10.1111/..

14

CML-423 Trial in Progress: A Phase III Study of Asciminib v..:

Hughes, Timothy P. ; Cortes, Jorge ; Takahashi, Naoto...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S297-S298 , 2022

Link: https://doi.org/10.1016/..

15

Mechanisms of Resistance and Implications for Treatment Str..:

Poudel, Govinda ; Tolland, Molly G. ; Hughes, Timothy P..
Cancers. 14 (2022) 14 - p. 3300 , 2022

Link: https://doi.org/10.3390/..